research use only
Cat.No.S1713
|
In vitro |
DMSO
: 66 mg/mL
(199.18 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 331.35 | Formula | C15H13N3O4S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 36322-90-4 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | CP 16171 | Smiles | CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3 | ||
| Targets/IC50/Ki |
COX
|
|---|---|
| In vitro |
Piroxicam induces activation of extracellular signal-regulated kinase (ERK) in neurones and phosphorylation of heavy molecular weight neurofilaments, cytoskeletal substrates of ERK in rat spinal cord cultures. This compound and NS-398 protect neurones against hypoxia/reperfusion in rat spinal cord cultures.
|
| In vivo |
Piroxicam at doses higher than 0.04%, strongly inhibits the development of GST-P-positive and neoplastic nodules as well as fibrosis, cirrhosis and formation of 8-hydroxydeoxyguanosine (8-OHdG) adducts in rats. This compound increases the expression of all three MHC antigens compared to either control or azoxymethane (AOM)-treated rats. It up-regulates colonic MHC antigen expression in the AOM model of colonic carcinogenesis. This chemical combined with Cisplatin has antitumor activity against oral malignant melanoma (OMM) and oral squamous cell carcinoma (SCC) in rats. It inhibits prostaglandin synthesis through cyclooxygenase blockade in dog, and does not have any direct cytotoxic effects in vitro. It also binds strongly to plasma proteins and could stop Ochratoxin A (OTA) -binding and transport into target organs, thereby preventing its nephrotoxicity in rats. This agent prevents the enzymuria induced by OTA and increases renal elimination of OTA in rats.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02253446 | Completed | Primary Dysmenorrhea |
Pamukkale University |
May 2013 | Phase 4 |
| NCT01320709 | Completed | Contraception Postcoital |
Bayer |
March 2011 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.